Physician profile

Ankit A Shah

Interventional Cardiology · Arlington Heights, IL

NPI 1962426056

$6,560.50

in general payments reported to CMS, 2019-2025

40 companies · $938 in 2025

The $938 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

See the full distribution for Interventional Cardiology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,508.03

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abiomed $1,248.13 2019-2025 Impella
Novartis Pharmaceuticals Corporation $767.62 2019-2025
Abbott Laboratories $610.41 2019-2025 Mitraclip, Cardiomems
Edwards Lifesciences Corporation $308.38 2019-2023
Amgen INC. $301.38 2019-2025 Repatha, Repatha
Merck Sharp & Dohme LLC $271.60 2021-2024 Verquvo
Boehringer Ingelheim Pharmaceuticals, INC. $269.62 2019-2025 Jardiance
Shockwave Medical, INC $262.80 2021-2023 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Boston Scientific Corporation $232.45 2019-2024 Watchman Flx
E.R. Squibb & Sons, L.L.C. $218.72 2019-2023 Camzyos
Pfizer INC. $199.67 2019-2025
Siemens Medical Solutions USA, INC. $195.22 2019
Janssen Pharmaceuticals, INC $193.45 2019-2024 Xarelto
Trisalus Life Sciences, INC. $171.30 2024-2025 Trinav Infusion System
Medtronic, INC. $158.42 2021-2025 Symplicity G3
Show all 40 companies
CompanyGeneral paymentsYearsTop products
Heartflow, INC. $145.30 2023-2025 Ffrct
Astrazeneca Pharmaceuticals LP $134.07 2019-2025 Farxiga, Brilinta
Philips North America LLC $115.90 2021-2023
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $91.83 2019-2024 Lifevest
Chiesi USA, INC. $78.09 2023-2025 Kengreal, Cleviprex
Teleflex LLC $58.32 2023-2025 Trapliner, Turnpike
Kiniksa Pharmaceuticals International, Plc $54.62 2024 Arcalyst
Bayer Healthcare Pharmaceuticals INC. $49.20 2025
Regeneron Healthcare Solutions, INC. $45.85 2019
Novo Nordisk INC $43.33 2022-2025 Wegovy
Sanofi-Aventis U.S. LLC $40.84 2019
Kowa Pharmaceuticals America, INC. $31.80 2020
Terumo Medical Corporation $29.08 2019
Alnylam Pharmaceuticals INC. $26.62 2025 Onpattro
Argon Medical Devices, INC. $26.37 2021
Lexicon Pharmaceuticals, INC. $21.41 2024
Actelion Pharmaceuticals US, INC. $21.03 2024 Uptravi
Akcea Therapeutics, INC. $20.75 2019
Kestra Medical Technology Services, INC. $19.76 2025 Assure Wcd
Esperion Therapeutics, INC. $19.54 2024 Nexletol
Rxsight INC $19.51 2023 Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge
Cardiva Medical, INC. $16.62 2022
Medtronic Vascular, INC. $16.06 2020
Amarin Pharma, INC. $13.56 2019
Cardinal Health 200 LLC $11.87 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ankit A Shah

$6,560.50

in general payments reported 2019-2025

Years
2019-2025
Top company
Abiomed
Context
The $938 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

https://glasscript.com/doctor/390507/ankit-a-shah

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.